Literature DB >> 1451237

Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.

F E Bishop1, C Dive, S Freeman, A Gescher.   

Abstract

Antineoplastic ether lipids have entered phase I clinical trial and, although their mechanism of action remains unclear, it is widely believed that the plasma membrane is the primary cellular drug target. In the present study the hypothesis was tested that metabolism of ether lipids acts as a detoxification process. [31P]-nuclear magnetic resonance (NMR) spectroscopy was used to study the metabolism of the ether lipid SRI 62-834 (SRI) and the phosphate ester hexadecylphosphocholine (HPC) in the presence of both isolated phospholipases C and D and post-mitochondrial rat liver homogenate. Both SRI and HPC were slowly metabolised by phospholipase D to their alkyl phosphates and choline, and the alkyl phosphates were subsequently metabolised by phosphatase to yield the alcohols and inorganic phosphate. These studies failed to detect any metabolism of either SRI or HPC by phospholipase C, and the metabolism of platelet-activating factor (PAF) by this enzyme was not inhibited by the addition of either compound. The cytotoxicity of SRI, the related compound HPC and their metabolites was determined in vitro using three cell lines. Cytotoxicity was measured by analysis of cell growth kinetics, MTT assay and lactate dehydrogenase release. Closely similar results were obtained in the JB1 rat hepatoma cell line, in the non-transformed BL8 rat hepatocyte cell line, and in A549 human lung adenocarcinoma cells. SRI was the most toxic of the compounds analysed, the concentration required to produce 50% toxicity or growth inhibition (IC50) being 6-9 microM. The putative metabolite of SRI, 2,2'-bis(hydroxymethyl)tetrahydrofuran, and the known metabolites [2'-(octadecyloxymethyl)tetrahydrofuran-2'-yl]methyl phosphate and 2-hydroxymethyl-2-octadecyloxymethyltetrahydrofuran exhibited IC50 values of > 200, > 100 and 40-70 microM, respectively, consistent with metabolic detoxification. HPC was more cytotoxic (IC50, 37 microM) than its phosphate metabolite (IC50, 140 microM), but its toxicity was similar to that of its metabolite hexadecanol (IC50, 28 microM), suggesting that only the former metabolic route leads to detoxification.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451237     DOI: 10.1007/bf00685092

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.

Authors:  G W Bazill; T M Dexter
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

Review 2.  Anti-tumor action of alkyl-lysophospholipids (Review).

Authors:  W E Berdel; W R Bausert; U Fink; J Rastetter; P G Munder
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

3.  Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834.

Authors:  C M Lazenby; M G Thompson; J A Hickman
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

4.  HL-60 cells become resistant towards antitumor ether-linked phospholipids following differentiation into a granulocytic form.

Authors:  D S Vallari; Z L Smith; F Snyder
Journal:  Biochem Biophys Res Commun       Date:  1988-10-14       Impact factor: 3.575

5.  Metabolism of platelet-activating factor in primary cultured adult rat hepatocytes by a new pathway involving phospholipase C and alkyl monooxygenase.

Authors:  T Okayasu; K Hoshii; K Seyama; T Ishibashi; Y Imai
Journal:  Biochim Biophys Acta       Date:  1986-03-21

6.  Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.

Authors:  C Dive; J V Watson; P Workman
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

7.  The effect of sn-2 fatty acid substitution on phospholipase C enzyme activities.

Authors:  J S Bomalaski; M A Clark
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

8.  Distribution and metabolism of hexadecylphosphocholine in mice.

Authors:  A Breiser; D J Kim; E A Fleer; W Damenz; A Drube; M Berger; G A Nagel; H Eibl; C Unger
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

9.  Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3.

Authors:  W J Houlihan; M L Lee; P G Munder; G M Nemecek; D A Handley; C M Winslow; J Happy; C Jaeggi
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

10.  A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity.

Authors:  P R Twentyman; M Luscombe
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more
  2 in total

1.  Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.

Authors:  I Fichtner; R Zeisig; H Naundorf; S Jungmann; D Arndt; G Asongwe; J A Double; M C Bibby
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

2.  Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.

Authors:  M Lohmeyer; P Workman
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.